Aquestive Therapeutics, Inc. Asset Retirement Obligation, Accretion Expense
Aquestive Therapeutics, Inc. (AQST) reported Asset Retirement Obligation, Accretion Expense of $8.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetRetirementObligationAccretionExpense · last filed 2026-08-11
- Aquestive Therapeutics, Inc. asset retirement obligation, accretion expense for the quarter ending 2026-06-30 was $8.00K, a 14.29% increase year-over-year.
- Aquestive Therapeutics, Inc. asset retirement obligation, accretion expense for the quarter ending 2026-03-31 was $7.00K, a 16.67% increase year-over-year.
- Aquestive Therapeutics, Inc. asset retirement obligation, accretion expense for the quarter ending 2025-06-30 was $7.00K.
- Aquestive Therapeutics, Inc. asset retirement obligation, accretion expense for the quarter ending 2025-03-31 was $6.00K.
- Aquestive Therapeutics, Inc. asset retirement obligation, accretion expense for fiscal 2025 was $26.00K, a 13.04% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. asset retirement obligation, accretion expense for fiscal 2024 was $23.00K, a 14.81% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. asset retirement obligation, accretion expense for fiscal 2023 was $27.00K, a 83.83% decline from fiscal 2022.
- Aquestive Therapeutics, Inc. asset retirement obligation, accretion expense for fiscal 2022 was $167.00K, a 10.70% decline from fiscal 2021.
| Period end | Asset Retirement Obligation, Accretion Expense 3 month | Asset Retirement Obligation, Accretion Expense 6 month | Asset Retirement Obligation, Accretion Expense 9 month | Asset Retirement Obligation, Accretion Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.00K 10-Q · filed 2026-08-11 | $15.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $7.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $26.00K 10-K · filed 2026-03-04 | |||
| 2025-06-30 | $7.00K 10-Q · filed 2026-08-11 | $13.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $6.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $23.00K 10-K · filed 2026-03-04 | |||
| 2023-12-31 | $27.00K 10-K · filed 2025-03-05 | |||
| 2022-12-31 | $167.00K 10-K · filed 2024-03-05 | |||
| 2021-12-31 | $187.00K 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $165.00K 10-K · filed 2022-03-08 | |||
| 2019-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $74.00K derived: sum of 2 quarters · filed 2021-03-09 | $110.00K derived: sum of 3 quarters · filed 2021-03-09 | $144.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $72.00K derived: sum of 2 quarters · filed 2019-11-05 | $106.00K 10-Q · filed 2019-11-05 | $134.00K derived: sum of 4 quarters · filed 2020-03-11 |
| 2019-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $70.00K 10-Q · filed 2019-08-06 | $98.00K derived: sum of 3 quarters · filed 2020-03-11 | $131.00K derived: sum of 4 quarters · filed 2020-03-11 |
| 2019-03-31 | $34.00K 10-Q · filed 2019-05-08 | $62.00K derived: sum of 2 quarters · filed 2020-03-11 | $95.00K derived: sum of 3 quarters · filed 2020-03-11 | $130.00K derived: sum of 4 quarters · filed 2020-03-11 |
| 2018-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $61.00K derived: sum of 2 quarters · filed 2020-03-11 | $96.00K derived: sum of 3 quarters · filed 2020-03-11 | $130.00K 10-K · filed 2020-03-11 |
| 2018-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $68.00K derived: sum of 2 quarters · filed 2019-11-05 | $102.00K 10-Q · filed 2019-11-05 | $134.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $69.00K 10-Q · filed 2019-08-06 | $101.00K derived: sum of 3 quarters · filed 2019-08-06 | $132.00K derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $34.00K 10-Q · filed 2019-05-08 | $66.00K derived: sum of 2 quarters · filed 2019-05-08 | $97.00K derived: sum of 3 quarters · filed 2019-05-08 | |
| 2017-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $63.00K derived: sum of 2 quarters · filed 2019-03-14 | $122.00K 10-K · filed 2019-03-14 | |
| 2017-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $90.00K 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $59.00K 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |